Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Dr. Amit Kumar es el Chairman of the Board de Anixa Biosciences Inc, se unió a la empresa desde 2012.
¿Qué tal es el rendimiento del precio de la acción ANIX?
El precio actual de ANIX es de $2.94, ha 下降 un 2.15% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Anixa Biosciences Inc?
Anixa Biosciences Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Anixa Biosciences Inc?
La capitalización bursátil actual de Anixa Biosciences Inc es $98.7M
¿Es Anixa Biosciences Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Anixa Biosciences Inc, incluyendo 2 fuerte compra, 7 compra, 1 mantener, 0 venta, y 2 fuerte venta